MEDVi Pills Review 2026: Compounded vs Wegovy Pill

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you searched “MEDVi pills reviews,” you probably hit the same wall most readers do: MEDVi sells two completely different oral products under the same “pill” banner, and most of the third-party reviews online are talking about a different one than you might be enrolling in. There is the MEDVi compounded semaglutide tablet (a daily dissolvable from a compounding pharmacy partner, advertised from $249/month) and the MEDVi Wegovy pill route (a $99/month membership plus the cost of the FDA-approved Wegovy oral semaglutide tablet from Novo Nordisk). They are not the same medication, they don’t have the same regulatory status, and they don’t cost the same thing in your bank account. This review walks the actual products, the verified pricing, the cancellation rules, and where PlexusDx Semaglutide Oral ($249/mo+) and the Microdose GLP-1 Protocol ($129/mo flat) sit relative to MEDVi for cash-pay readers who want a non-injection GLP-1.

MEDVi Pills: the two products, untangled

The single biggest source of confusion in MEDVi reviews is that “the pill” refers to two different things depending on which corner of MEDVi’s site you land on. The first is MEDVi’s compounded semaglutide dissolvable tablet, prepared by a compounding pharmacy partner and listed from $249/month with the consultation, prescription, and shipping bundled into one bill. Compounded tirzepatide tablets are listed from $279/month on the same path. These are not FDA-approved finished drug products; the FDA does not review compounded medications for safety, effectiveness, or quality before they reach patients. The second product is the MEDVi Wegovy pill route — a $99/month membership that gives you access to a MEDVi-affiliated provider who can prescribe the FDA-approved Wegovy oral semaglutide tablet from Novo Nordisk; you pay separately for the medication itself, typically $149–$299/month through NovoCare depending on dose. Most MEDVi reviews online describe the compounded tablet, not the branded Wegovy pill route — and that gap is exactly why the search query exists. PlexusDx Semaglutide Oral sits in the same category as MEDVi’s compounded tablet (compounded oral GLP-1, not FDA-approved as a finished product), starting at $249/mo with consultation, medication, and shipping included — and PlexusDx Microdose GLP-1 Protocol offers a flat $129/month entry-level option in capsule, troche, lozenge, or sublingual delivery.

Real cost: what MEDVi actually charges

For the compounded tablet path, MEDVi publishes pricing starting at $249/month for compounded semaglutide tablets and $279/month for compounded tirzepatide tablets, with the consult and shipping bundled. Third-party reviews report ongoing pricing closer to $369/month after the introductory tier, so a 12-month total typically lands in the $3,200–$4,400/year range depending on dose and tier. For the Wegovy pill route, the membership is $99/month plus $149–$299/month for the FDA-approved oral semaglutide tablet through NovoCare, producing an estimated $248–$398/month all-in — roughly $2,976–$4,776/year. By comparison, PlexusDx Semaglutide Oral at $249/mo+ totals $2,508/year at the entry tier with consultation, compounded oral semaglutide, and shipping in one bill, and the Microdose GLP-1 Protocol at $129/mo flat totals $1,548/year. None of the three options bills insurance directly — all are cash-pay; PlexusDx adds no membership fee on top of protocol pricing.

Compounded tablet vs FDA-approved oral semaglutide

This is the substantive medication question and it matters more than monthly price for most readers. The FDA-approved Wegovy pill (oral semaglutide for weight management) is the same active ingredient as the Wegovy injection, formulated with a specialized absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) that allows enough semaglutide to cross the stomach lining to reach therapeutic blood levels. It runs on the OASIS 4 trial evidence base — about 14% body-weight loss over 64 weeks at the highest dose. MEDVi’s compounded semaglutide tablet uses the same active ingredient prepared by a compounding pharmacy, but the finished compounded product has not undergone FDA review and does not have a published trial. The same regulatory framing applies to PlexusDx Semaglutide Oral — it is compounded oral semaglutide dosed 3mg to 24mg daily across six dose levels, not an FDA-approved finished drug. The compounded vs branded choice is not a question about whether the active ingredient works — semaglutide is semaglutide. It is a question about whether you want the FDA-approved finished tablet (in which case the Wegovy pill via NovoCare or a telehealth platform is the right path) or a compounded version dispensed by a licensed U.S. compounding pharmacy at a meaningfully lower monthly cost.

Cancellation, the 72-hour rule, and refunds

MEDVi requires cancellation at least 72 hours before your next billing date. Per MEDVi’s published policy, cancellations not tied to medical disqualification do not receive a refund — you keep what has already shipped, but the next month’s payment is what stops, not the previous one. This is worth knowing before you sign up because the auto-renew billing happens on the same calendar cycle as your initial charge, and missing the 72-hour window means another month of charges. PlexusDx Weight Management Protocols, including Semaglutide Oral and the Microdose GLP-1 Protocol, are also cash-pay with no membership; cancellation rules are protocol-specific and disclosed at checkout. Whichever route you take, read the cancellation language before you enter payment details — cash-pay GLP-1 platforms vary widely on auto-renew terms and refund eligibility.

The February 2026 FDA warning letter — what it does and doesn’t mean

In February 2026, the FDA issued a warning letter addressing marketing language on a MEDVi-affiliated site (medvi.io). The letter cited misbranding — specifically, language that allegedly implied FDA approval of compounded products. The letter did not allege contaminated medication, improperly prepared product, or harm to patients; it focused on advertising claims. For a reader weighing MEDVi, the takeaway is narrow: the company received a regulatory communication about how it described its compounded medications, not about the safety of the medications themselves. It is, however, a useful reminder that compounded semaglutide and tirzepatide — whether from MEDVi, PlexusDx, or any other platform — are not FDA-approved finished products and shouldn’t be marketed as if they were. PlexusDx Semaglutide Oral and the Microdose GLP-1 Protocol are compounded preparations from licensed U.S. compounding pharmacies; the boxed warning for thyroid C-cell tumors that applies to FDA-approved semaglutide and tirzepatide (based on rodent studies) applies to the active ingredients in the compounded versions as well.

Where PlexusDx fits if you want a non-injection GLP-1

If you came to MEDVi specifically because you wanted to avoid weekly injections, PlexusDx covers the same intent with two protocols at lower published prices than MEDVi’s compounded tablet path. The Semaglutide Oral protocol is compounded oral semaglutide dosed 3mg to 24mg daily across six dose levels, starting at $249/mo all-inclusive (consultation, compounded medication, shipping). The Microdose GLP-1 Protocol is a $129/month flat-price entry tier that uses compounded GLP-1 across four delivery formats — capsule, troche, lozenge, and sublingual — with provider-selected dosing, useful for readers who want to start low and escalate slowly, or who are sensitive to GI side effects on standard titration. PlexusDx also offers compounded oral tirzepatide via the Tirzepatide Oral protocol ($279/mo across seven dose levels) for readers who specifically want a dual-agonist pill route. All three are cash-pay, available in all 50 states, with no membership fee; five states require a scheduled live consult rather than async intake.

Why genetics belong in the oral GLP-1 conversation

Oral GLP-1 absorption and response are not uniform across patients. Variants in GLP1R (the GLP-1 receptor itself), GIPR (rs1800437 in particular, associated with differential GLP-1 response), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are linked to measurably different response patterns to semaglutide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights — and is available at $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. Neither MEDVi’s compounded tablet path nor its Wegovy pill route includes a genetic baseline; both start from a population-average titration and adjust based on subjective tolerability over the first 8–12 weeks. If you have already tried an oral or injectable GLP-1 and either tolerated it poorly or didn’t respond as expected, the genetic baseline is the variable most worth adding before your next attempt — the same active ingredient can produce very different outcomes across GLP1R and GIPR genotypes.

Who MEDVi’s pill products fit — and who should consider PlexusDx instead

MEDVi’s compounded tablet may make sense if you specifically want a daily dissolvable tablet from a compounding pharmacy and you’re comfortable with the $249–$369/month range. MEDVi’s Wegovy pill route may make sense if you want the FDA-approved branded oral semaglutide tablet specifically and you don’t mind the $99 membership on top of the $149–$299 medication cost. PlexusDx Semaglutide Oral at $249/mo+ fits readers who want a compounded daily oral GLP-1 with all-inclusive pricing and no membership fee, in any of the 50 states. PlexusDx Microdose GLP-1 Protocol at $129/mo flat fits readers who want the lowest-cost cash-pay entry into compounded oral GLP-1, multiple delivery options, and a starting point that can be titrated up by the prescribing provider. And the Precision Peptide Genetic Test ($99 add-on after month one) fits readers who want their next dose decision anchored to GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants rather than another round of trial-and-error.

Frequently asked questions

Is MEDVi’s pill the same as Wegovy?

No. MEDVi sells two different oral products: a compounded semaglutide tablet (not FDA-approved as a finished drug) and a Wegovy pill route that adds a $99/month membership on top of the medication cost. Most MEDVi reviews describe the compounded tablet, not the branded Wegovy path. PlexusDx Semaglutide Oral is also compounded, starting at $249/mo with no membership fee.

Are MEDVi’s compounded tablets FDA-approved?

No. Compounded semaglutide and tirzepatide tablets are not FDA-approved as finished products. They are prepared by compounding pharmacy partners and have not undergone FDA review for safety, effectiveness, or quality. The same regulatory framing applies to PlexusDx Semaglutide Oral and the Microdose GLP-1 Protocol, both of which are compounded preparations from licensed U.S. compounding pharmacies.

How much does the Wegovy pill cost through MEDVi?

MEDVi’s Wegovy pill route is $99/month membership plus the medication itself, which NovoCare publishes at $149–$299/month depending on dose. The estimated all-in is roughly $248–$398/month. PlexusDx Semaglutide Oral starts at $249/mo all-inclusive with no membership fee on top.

Can I cancel MEDVi anytime?

MEDVi requires cancellation at least 72 hours before your next billing date, and per the published policy, cancellations not tied to medical disqualification do not receive a refund. Read the cancellation terms at checkout before entering payment details — auto-renew rules vary across cash-pay GLP-1 platforms.

Does MEDVi accept insurance?

No. MEDVi prescriptions are cash-pay; insurance is not billed directly. Some patients pursue out-of-network reimbursement for FDA-approved branded medications, but the compounded tablet path is generally not covered. PlexusDx is also cash-pay across all six Weight Management Protocols.

Is there an FDA-approved tirzepatide pill?

No. As of April 2026, tirzepatide is FDA-approved only as a weekly injection (Mounjaro for type 2 diabetes, Zepbound for weight management). Any “tirzepatide pill” on the market is a compounded product, including MEDVi’s compounded tirzepatide tablet and PlexusDx’s Tirzepatide Oral protocol.

What if MEDVi’s oral GLP-1 doesn’t work for me?

Roughly 24% of participants in the OASIS 4 trial of FDA-approved oral semaglutide did not lose 5% or more body weight; for compounded formulations, the response range is broader. If you don’t see results after reaching an adequate dose with proper adherence, talk to your provider about alternatives — switching to weekly injection, adding the Precision Peptide Genetic Test for a GLP1R/GIPR baseline, or escalating to a dual-agonist option like PlexusDx GLP-Squared.

MEDVi Pills Review (2026): Compounded Tablet vs Wegovy Pill vs PlexusDx Oral GLP-1 | PlexusDx